# A Clinical Trial to Compare Efficacy and Tolerability of Fulvestrant 250mg, 250mg (Plus 250mg Loading Regimen) and 500mg

> **NCT00305448** · PHASE2 · COMPLETED · sponsor: **AstraZeneca** · enrollment: 143 (actual)

## Conditions studied

- Advanced Breast Cancer
- Metastatic Breast Cancer

## Interventions

- **DRUG:** Fulvestrant
- **DRUG:** Fulvestrant

## Key facts

- **NCT ID:** NCT00305448
- **Lead sponsor:** AstraZeneca
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2006-03
- **Primary completion:** 2008-03
- **Final completion:** 2012-02
- **Target enrollment:** 143 (ACTUAL)
- **Last updated:** 2012-02-15


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00305448

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00305448, "A Clinical Trial to Compare Efficacy and Tolerability of Fulvestrant 250mg, 250mg (Plus 250mg Loading Regimen) and 500mg". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT00305448. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*